Independent ethics committee curbs seen hurting Indian studies
This article was originally published in SRA
Following on from the Supreme Court of India issuing strict time-bound instructions to the government concerning the regulatory regime for clinical trials, a new notice restricting the scope of activities of independent ethics committees (ECs) is expected to have a crushing impact on investigator-led and post-marketing studies in the country1.
You may also be interested in...
India's draft revised ethical guidelines for biomedical and health research involving human participants covers a raft of new and existing segments. It expands on "specialized" areas such as "informed consent" and "vulnerability" – complex and delicate issues in the Indian context - but some experts say that the multiplicity of "overlapping" rules and guidelines could complicate compliance efforts.
Legal experts explain why India’s plans to abolish the Intellectual Property Appellate Board and shift its powers to courts may be problematic for stakeholders, including those pursuing infringement charges. The transition could mean a significant burden on courts both in terms of capability and capacity, and IPR cases will now conflate into all other pending commercial matters, some experts said, though others cheered the proposed change.
Ex-Novartis executive and co-founder of investment bank MM Dillon & Co shares insights around where healthcare unicorns can be found and some core criteria to build such firms.